Quarterly report · Q3
2385.TEDINET S100TEAA
Period2023-07-01 → 2024-03-31
Filed2024-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.8bn | 2023-07-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥8.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.6bn | 2022-07-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | −¥560m | 2023-07-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥785m | 2022-07-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | −¥529m | 2023-07-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥785m | 2022-07-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥529m | 2023-07-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥784m | 2022-07-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥575m | 2023-07-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥452m | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥496m | 2022-07-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥575m | 2023-07-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥500m | 2022-07-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥7.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥8.7bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥641m | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥-21.96 | 2023-07-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.31 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.27 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.97 | 2022-07-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.97 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 90.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 49
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-03-31 | −¥17m |
| Reconciling Itemsreconciling | revenue external | 2023-07-01 → 2024-03-31 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-03-31 | −¥19m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-03-31 | −¥225m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥192m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥192m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥51m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥982m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥982m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥177m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥6m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥184m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥255m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥242m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | segment profit | 2023-07-01 → 2024-03-31 | −¥686,000 |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue | 2023-07-01 → 2024-03-31 | ¥490m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue external | 2023-07-01 → 2024-03-31 | ¥490m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | segment profit | 2023-07-01 → 2024-03-31 | ¥78m |
| —segment total | revenue | 2023-07-01 → 2024-03-31 | ¥3.9bn |
| —segment total | revenue external | 2023-07-01 → 2024-03-31 | ¥3.8bn |
| —segment total | revenue intersegment | 2023-07-01 → 2024-03-31 | ¥19m |
| —segment total | segment profit | 2023-07-01 → 2024-03-31 | −¥336m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue external | 2022-07-01 → 2023-03-31 | ¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-03-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-03-31 | −¥226m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥404m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥404m |
| jpcrp040300-q3r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥68m |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥3.4bn |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥3.4bn |
| jpcrp040300-q3r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥701m |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥1.9bn |
| jpcrp040300-q3r_E05367-000Functional Food Retailingreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥115m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥382m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥380m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥3m |
| jpcrp040300-q3r_E05367-000Functional Material Developmentreportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥43m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue | 2022-07-01 → 2023-03-31 | ¥463m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | revenue external | 2022-07-01 → 2023-03-31 | ¥463m |
| jpcrp040300-q3r_E05367-000Health Care Support Servicereportable segment | segment profit | 2022-07-01 → 2023-03-31 | ¥83m |
| —segment total | revenue | 2022-07-01 → 2023-03-31 | ¥6.6bn |
| —segment total | revenue external | 2022-07-01 → 2023-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2022-07-01 → 2023-03-31 | ¥3m |
| —segment total | segment profit | 2022-07-01 → 2023-03-31 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 314
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 982014000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1933466000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 242024000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 3840069000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | 1200000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 3841269000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 5980000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 12557000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 18537000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -18537000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 192314000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 490249000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 982014000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1939447000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 254581000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 3858607000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -17337000 | JPY |
| Net sales | CurrentYTDDuration | 3841269000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | -51150000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 77640000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | -177462000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -183959000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | -686000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -335618000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -224702000 | JPY |
| Operating income | CurrentYTDDuration | -560320000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第30期第３四半期（自 2024年１月１日 至 2024年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社総医研ホールディングス | |
| Company name in english cover page | FilingDateInstant | Soiken Holdings Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 石神 賢太郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府豊中市新千里東町一丁目４番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06（6871）8888 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)財務部長 奥野 貴人 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府豊中市新千里東町一丁目４番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06（6871）8888 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)財務部長 奥野 貴人 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05367 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 23850 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社総医研ホールディングス | |
| Filer name in english | FilingDateInstant | Soiken Holdings Inc. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |